We advised Alebund Pharmaceuticals on its IPO and HKEX listing

Davis Polk advised Alebund Pharmaceuticals (Jiangsu) Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and its international offering pursuant to Regulation S and Rule 144A. The net proceeds of the offering were approximately HK$1.28 billion. Jefferies Hong Kong Limited, Merrill Lynch (Asia Pacific) Limited and Huatai Financial Holdings (Hong Kong) Limited acted as the joint sponsors and the sponsor-overall coordinators. Jefferies, Merrill Lynch, Huatai and CLSA Limited acted as the joint representatives. Jefferies, Merrill Lynch, Huatai, CLSA and BOCI Asia Limited acted as the overall coordinators, the joint global coordinators, the joint bookrunners, the joint lead managers and the capital market intermediaries.

Founded in 2018, Alebund Pharmaceuticals is a biopharmaceutical company providing renal therapies, with the broadest drug candidates in terms of renal indication coverage globally.

The Davis Polk corporate team included partners Xuelin (Steve) Wang and Jason Xu and counsel Wendy Kan. Associate Kelli A. Rivers provided tax advice. Members of the Davis Polk team are based in the Hong Kong, Beijing, and London offices.

Copy link to share post